Explore the words cloud of the DIRECtA project. It provides you a very rough idea of what is the project "DIRECtA" about.
The following table provides information about the project.
FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD
|Coordinator Country||Spain [ES]|
|Total cost||158˙121 €|
|EC max contribution||158˙121 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2018-01-03 to 2020-01-02|
Take a look of project's partnership.
|1||FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD||ES (MALAGA)||coordinator||158˙121.00|
Europe has the highest prevalence per capita of children with type 1 diabetes (T1D), an autoimmune disease with no cure that results in progressive destruction, and finally an absolute loss, of insulin-producing beta (β) cells in islets of Langerhans in the pancreas. This means that patients require exogenous insulin administration for life. Additionally, prolonged uncontrolled blood glucose levels increase the risk of cardiovascular diseases, peripheral neuropathy, renal failure and numerous infections. The endocannabinoid receptors (ECRs) CB1, CB2 and GPR55 are regulators of metabolism and immune action and are also present on β cells. Cannabidiol, a CB1 antagonist, reduced the incidence of T1D in mice by reducing insulitis, thereby preserving β cell mass. Additionally, blockade of CB1 alters insulin secretion, increasing proliferation and autophagy in β cells. Importantly, β cell-specific CB1 knockout mice have no T-cell infiltration in islets when their pancreas is challenged. Furthermore, activation of GPR55 and CB2 are reported to be beneficial in protecting from inflammation. In this project we intend to study the interaction of the ECRs and their potential synergy for protecting β cells from insulitis. For this purpose, we will generate a non-obese diabetic (spontaneously develops autoimmune insulitis) β cell-specific CB1 knockout mouse, and use pharmacological approaches to enhance GPR55 and CB2 signalling to determine if the diabetic condition can be prevented/ameliorated. We will assess β cell damage together with mitochondrial function, autophagy, and inflammatory responses in our mouse model and after pharmacological manipulation. Thus, this project proposes a new strategy, not focusing on the immune system but on the role that β cells themselves play in modulating their own reactivity, for the development of new therapies for preventing and/or treating T1D.
|year||authors and title||journal||last update|
Silvana Y. Romero-Zerbo, MarÃa GarcÃa-FernÃ¡ndez, Vanesa Espinosa-Jimenez, Macarena Pozo-Morales, Alejandro Escamilla-SÃ¡nchez, Lourdes SÃ¡nchez-Salido, Estrella Lara, Nadia Cobo-Vuilleumier, Alex Rafacho, Gabriel Olveira, Gemma Rojo-MartÃnez, Benoit R. Gauthier, Isabel GonzÃ¡lez-Mariscal and Francisco J. BermÃºdez-Silva
THE ATYPICAL CANNABINOID ABN-CBD REDUCES INFLAMMATION AND PROTECTS LIVER, PANCREAS AND ADIPOSE TISSUE IN A MOUSE MODEL OF PREDIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE
published pages: , ISSN: 1664-2392, DOI: 10.3389/fendo.2020.00103
|Frontiers in Endocrinology||2020-03-05|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIRECTA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DIRECTA" are provided by the European Opendata Portal: CORDIS opendata.